Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-03-15

FDA Approved: DIFICID — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approves a supplemental application for DIFICID (fidaxomicin) by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dificid (fidaxomicin)

Snippet

SUPPL AP for DIFICID (FIDAXOMICIN)